Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Propranolol
Drug ID BADD_D01867
Description Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors.[L6904] Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.[L6904]
Indications and Usage Propranolol is indicated to treat hypertension.[L6907,L6904] Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.[L6904,L6907]
Marketing Status approved; investigational
ATC Code C07AA05
DrugBank ID DB00571
KEGG ID D08443
MeSH ID D011433
PubChem ID 4946
TTD Drug ID D04JEE
NDC Product Code Not Available
UNII 9Y8NXQ24VQ
Synonyms Propranolol | Propanolol | Inderal | Avlocardyl | AY-20694 | AY 20694 | AY20694 | Rexigen | Dexpropranolol | Dociton | Obsidan | Obzidan | Propranolol Hydrochloride | Hydrochloride, Propranolol | Anaprilin | Anapriline | Betadren
Chemical Information
Molecular Formula C16H21NO2
CAS Registry Number 525-66-6
SMILES CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Peripheral arterial occlusive disease24.04.03.010--Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.000315%Not Available
Dark circles under eyes08.01.03.054; 06.08.03.0190.000118%Not Available
Neuropsychological test abnormal13.07.06.001--Not Available
Bronchial hyperreactivity22.03.01.0160.000160%Not Available
Treatment failure08.06.01.0170.000710%Not Available
Liver injury12.01.17.012; 09.01.07.0220.000080%Not Available
Regurgitation07.01.07.0040.000272%Not Available
Brain injury19.07.03.007; 17.11.01.0030.000053%Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.008--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.000331%
Mechanical urticaria23.04.02.004; 10.01.06.0040.000053%Not Available
Hypoxic-ischaemic encephalopathy24.04.06.021; 22.02.02.011; 17.13.02.0060.000053%Not Available
Foetal growth restriction18.03.01.0020.000240%
Slow speech19.19.02.004; 17.02.08.0160.000053%Not Available
Substance-induced psychotic disorder19.03.01.007; 12.03.01.0530.000187%Not Available
Faeces soft07.01.03.0080.000272%Not Available
Encapsulating peritoneal sclerosis07.07.03.0040.000053%Not Available
Respiratory symptom22.12.02.0130.000235%Not Available
Sinus node dysfunction02.03.03.0170.000134%
Feeding intolerance18.04.11.003; 14.02.01.0060.000107%Not Available
Apnoeic attack22.02.01.027; 17.02.05.0510.000080%Not Available
Coeliac disease14.02.01.007; 10.04.04.012; 07.17.01.0080.000235%Not Available
Mesenteric vein thrombosis24.01.08.004; 07.15.02.0130.000053%Not Available
Pupil fixed17.02.11.008; 06.05.03.0120.000080%Not Available
Small for dates baby18.04.02.0020.000053%Not Available
Wolff-Parkinson-White syndrome02.03.01.0160.000080%Not Available
Accelerated idioventricular rhythm02.03.04.0170.000107%Not Available
Bradycardia neonatal18.04.07.004; 02.03.02.0190.000187%Not Available
Peripheral artery occlusion24.04.03.022--Not Available
The 13th Page    First    Pre   13 14    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene